Condensed Consolidated Income Statements (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues	$ 47,399	$ 38,646	$ 138,873	$ 107,627
Cost of revenues	25,778	19,797	74,570	54,218
Gross profit	21,621	18,849	64,303	53,409
Operating expenses:
Research and development	2,352	4,180	8,254	13,704
Clinical operations, net	1,677	1,405	4,802	4,681
Sales and marketing	12,337	13,184	38,615	39,698
General and administrative	5,156	5,259	17,698	15,952
Total operating expenses	21,522	24,028	69,369	74,035
Income (loss) from operations	99	(5,179)	(5,066)	(20,626)
Financial (income), net	(1,701)	(779)	(5,123)	(2,915)
Income (loss) before taxes on income	1,800	(4,400)	57	(17,711)
Taxes on income	(74)	14	123	165
Net income (loss)	$ 1,874	$ (4,414)	$ (66)	$ (17,876)
Net income (loss) per share:
Earnings Per Share, Basic	$ 0.01	$ (0.03)	$ (0)	$ (0.11)
Earnings Per Share, Diluted	$ 0.01	$ (0.03)	$ (0)	$ (0.11)
Weighted average shares used to compute net income (loss) per share:
Basic	168,426,349	166,570,673	168,805,882	164,215,802
Diluted	173,753,763	166,570,673	168,805,882	164,215,802